Vol 55, No 1 (2017)
Original paper
Published online: 2017-03-23

open access

Page views 1208
Article views/downloads 1363
Get Citation

Connect on Social Media

Connect on Social Media

Decreased expression of survivin 2B in human pituitary adenomas. A preliminary study

Joanna Waligorska-Stachura, Nadia Sawicka-Gutaj, Maciej Zabel, Wlodzimierz Liebert, Pawel Gut, Agata Czarnywojtek, Marek Ruchala
Pubmed: 28509313
Folia Histochem Cytobiol 2017;55(1):21-25.

Abstract

Introduction. We aimed to investigate survivin and its splice variants DEx3 and 2B expressions in pituitary adenomas and normal pituitary glands using immunohistochemistry.

Material and methods. The study group consisted of eight pituitary adenomas: five of non-functional tumors, two of GH-secreting tumors, and one PRL-secreting tumor. Eight healthy pituitary tissue samples obtained after autopsy served as controls.

Results. Survivin expression was found in 87.5% of the study group and 100% of the controls. A positive staining of survivin 2B was found in 62.5% of pituitary adenomas and 100% of controls. Survivin DEx3 was recognized in 25% of pituitary adenomas and 12.5% of normal pituitary glands. There was significantly lower immunoreactivity of survivin 2B in pituitary adenomas when compared with normal pituitary glands (p = 0.0498).

Conclusions: Survivin and its splice variants might be involved to some extent in benign tumor growth of pituitary adenomas. However, survivin cannot be regarded as a candidate for targeted therapy or molecular biomarker of pituitary adenomas.

Article available in PDF format

View PDF Download PDF file

References

  1. Ezzat S, Asa SL, Couldwell WT, et al. The prevalence of pituitary adenomas: a systematic review. Cancer. 2004; 101(3): 613–619.
  2. Fernandez A, Karavitaki N, Wass JAH. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010; 72(3): 377–382.
  3. Gruppetta M, Mercieca C, Vassallo J. Prevalence and incidence of pituitary adenomas: a population based study in Malta. Pituitary. 2013; 16(4): 545–553.
  4. Vandeva S, Tichomirowa MA, Zacharieva S, et al. Genetic factors in the development of pituitary adenomas. Endocr Dev. 2010; 17: 121–133.
  5. Jiang X, Zhang X. The molecular pathogenesis of pituitary adenomas: an update. Endocrinol Metab (Seoul). 2013; 28(4): 245–254.
  6. Dworakowska D, Grossman AB. The molecular pathogenesis of pituitary tumors: implications for clinical management. Minerva Endocrinol. 2012; 37: 157–172.
  7. Jia W, Lu R, Jia G, et al. Expression of pituitary tumor transforming gene (PTTG) in human pituitary macroadenomas. Tumour Biol. 2013; 34(3): 1559–1567.
  8. Li Y, Zhou LP, Ma P, et al. Relationship of PTTG expression with tumor invasiveness and microvessel density of pituitary adenomas: a meta-analysis. Genet Test Mol Biomarkers. 2014; 18(4): 279–285.
  9. Fukuoka H, Takahashi Y. The role of genetic and epigenetic changes in pituitary tumorigenesis. Neurol Med Chir (Tokyo). 2014; 54 Suppl 3(12): 943–957.
  10. Seltzer J, Ashton CE, Scotton TC, et al. Gene and protein expression in pituitary corticotroph adenomas: a systematic review of the literature. Neurosurg Focus. 2015; 38(2): E17.
  11. Pawlikowski M, Radek M, Kunert-Radek J, et al. Overexpression of prothymosin alpha is related to pituitary adenoma recurrence but not to adenoma invasiveness and proliferation. Endokrynol Pol. 2014; 65(5): 382–386.
  12. Żebracka-Gala J, Rudnik A, Hasse-Lazar K, et al. Molecular classification of pituitary adenomas: in search for criteria useful for high-throughput studies. Endokrynol Pol. 2016; 67(2): 148–156.
  13. Waligórska-Stachura J, Jankowska A, Waśko R, et al. Survivin – prognostic tumor biomarker in human neoplasms – review. Ginekol Pol. 2012; 83(7): 537–540.
  14. Sawicka-Gutaj N, Waligórska-Stachura J, Andrusiewicz M, et al. Nicotinamide phosphorybosiltransferase overexpression in thyroid malignancies and its correlation with tumor stage and with survivin/survivin DEx3 expression. Tumour Biol. 2015; 36(10): 7859–7863.
  15. Waligórska-Stachura J, Andrusiewicz M, Sawicka-Gutaj N, et al. Survivin delta Ex3 overexpression in thyroid malignancies. PLoS One. 2014; 9(6): e100534.
  16. Wasko R, Waligorska-Stachura J, Jankowska A, et al. Coexpression of survivin and PCNA in pituitary tumors and normal pituitary. Neuro Endocrinol Lett. 2009; 30(4): 477–481.
  17. Jankowska A, Wasko R, Waligorska-Stachura J, et al. Survivin products in pituitary tumors. Neuro Endocrinol Lett. 2008; 29(6): 1033–1037.
  18. Wasko R, Jankowska A, Waligorska-Stachura J, et al. Survivin expression in pituitary adenomas. Neuro Endocrinol Lett. 2005; 26(3): 209–212.
  19. Formosa R, Gruppetta M, Falzon S, et al. Expression and clinical significance of Wnt players and survivin in pituitary tumours. Endocr Pathol. 2012; 23(2): 123–131.
  20. Zhang Yc, Gao J, Xin T, et al. Expression of survivin in invasive pituitary adenoma. Saudi Med J. 2008; 29(11): 1589–1592.
  21. Waligórska-Stachura J, Andrusiewicz M, Sawicka-Gutaj N, et al. Evaluation of survivin splice variants in pituitary tumors. Pituitary. 2015; 18(3): 410–416.
  22. Remmele W, Stegner HE. Vorschlag zur einheitlichen Definition eines immunreaktiven Score (IRS) fur den Immunohistochemichen Ostrogenrezeptor-Nachweis (ER-ICA) im Mammikarzinomgewebe. Patologie. 1987; 8: 138–140.
  23. Krieg A, Mahotka C, Krieg T, et al. Expression of different survivin variants in gastric carcinomas: first clues to a role of survivin-2B in tumour progression. Br J Cancer. 2002; 86(5): 737–743.